Objective: We report updated results at a median follow-up of 12 years of a phase II trial assessing first-line MATILDE chemotherapy and response-tailored radiotherapy in patients with primary CNS lymphomas (PCNSL).
High-dose methotrexate (MTX)-chemotherapy with or without subsequent whole-brain radiotherapy (WBRT) is the most commonly used first-line treatment for immunocompetent patients with primary CNS lymphomas (PCNSL). 1 Several trials addressing new treatment strategies have been published, sometimes showing encouraging results, with or without a plateau in the survival curves. The latter is an important issue as survival plateau after a long follow-up may be synonymous with cure in aggressive malignancies like PCNSL. However, data from these trials were often published after a short follow-up, while updates on mature results, which have been rarely reported, 2,3 have frustratingly showed a continuous downward slope of survival curves, mostly due to late relapses and unrelated deaths. Late relapses occur in 1%-3% of patients with PCNSL in large retrospective series, affecting the 15% of patients followed 5 years or more. 4, 5 Thus, the report of updated results of prospective trials after a median follow-up of .10 years may provide crucial information on definitive cure of PCNSL.
Seven years ago, we reported the outcome of a phase II trial addressing MATILDE chemotherapy (high doses of MTX and cytarabine plus idarubicin and thiotepa) followed by response-tailored radiotherapy in 41 patients #70 years old with PCNSL. 6 Chemotherapy 6 radiotherapy has been associated with an overall response rate of 83%, with a "plateau" in survival curve after a median follow-up of 49 months. We report results of this trial updated after a median follow-up of 144 months.
METHODS Forty-one HIV-negative adults (18-70 years; Eastern Cooperative Oncology Group performance status #3) with histologically confirmed PCNSL were enrolled between 2000 and 2004 (table). Patients received 3 courses of MATILDE chemotherapy (MTX 3.5 g/m 2 day 1; cytarabine 1.7 g/m 2 3 2/d day 2; idarubicin 13 mg/m 2 day 2; thiotepa 20 mg/m 2 day 3) followed by WBRT. 6 WBRT field included the segments C 1 2C 2 of the spinal cord and the posterior two-thirds of the orbits; WBRT dose was 30 Gy in patients with complete remission (CR) after MATILDE, 36 Gy in patients with partial response (PR), and 45 Gy in patients with stable or progressive disease, followed by a 9-Gy tumor-bed boost. Neurocognitive deterioration was assessed by Mini-Mental State Examination (MMSE) before and after treatment and every 6 months afterward. At the time this trial was designed, consensus on the best neuropsychological tests was lacking and MMSE was the most commonly used test in PCNSL trials. CR rate after MATILDE regimen was the primary endpoint (for statistical design, see original article 6 ). The primary research question of the present update regards the effect of late relapses on the originally reported survival plateau achieved with MATILDE and WBRT in patients with PCNSL.
Standard protocol approvals, registrations, and patient consents. The trial was conducted according to the International Conference on Harmonisation Harmonized Tripartite Guideline for Good Clinical Practice and was approved by institutional ethical committees of every participating center. A written informed consent was obtained from all patients (or guardians of patients) participating in the study.
RESULTS
After MATILDE chemotherapy, 18 patients achieved CR (CR rate 44%; 95% confidence interval [CI] 30%-58%) and 13 had PR (overall response rate 76%; 95% CI 63%-89%). Twenty-four of the 31 patients who achieved an objective response to MATILDE received WBRT; 7 responders refused radiotherapy. At the end of chemotherapy 6 radiotherapy, 23 patients had CR (56%; 95% CI 41%-71%) and 11 had PR (overall response rate 83%; 95% CI 71%-95%).
At a median follow-up of 144 months (range 47-153), 31 patients experienced an event: relapse after response in 24 patients, primary progressive disease in 3, and toxic death in 4 (septic shock in 2, stroke, Steven-Johnson syndrome), with a 5-year progression-free survival (PFS) of 24% 6 8% (figure, A). Failure (relapse, progression) involved the primary site of disease in 23 patients (plus positive CSF in 2 of them), spinal cord in 1, and extra-CNS organs in 3 patients. Nineteen patients received salvage treatment (temozolomide monotherapy in 10, CHOP chemotherapy followed by high-dose chemotherapy supported by autologous stem cell transplantation [HDC/ASCT] 
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Brain 1 cerebellum 1 meninges 1 (2) 0 (0) in 3, radiotherapy in 3, procarbazine in 2, MATILDE retreatment in 1). Four patients achieved a second CR; 3 had a transient PR. Only 2 failed patients are long-term survivors: both of them had extraneural relapse at 44 and 100 months and were salvaged after HDC/ASCT; they are alive and disease-free at 142 and 153 months. Apart from this patient with extraneural relapse at 100 months, there was another patient with a late brain failure (101 months); she was retreated with MATILDE with transient remission; she died of lymphoma at 110 months from diagnosis. One patient was lost to follow-up while relapse-free at 47 months from diagnosis. Nine patients are alive and disease-free, with a 5-year and 10-year overall survival (OS) of 30% 6 7% and 24% 6 7%, respectively ( figure, A) . Thirty-two patients died of lymphoma (n 5 24), toxicity (n 5 4), or unrelated causes while disease-free (n 5 4). OS was .10 years in 8 survivors. The International Extranodal Lymphoma Study Group (IELSG) score 7 was independently associated with survival, with a 5-year OS of 70%, 27%, and 11% (p 5 0.0002), respectively, for patients with low, intermediate, and high IELSG score (figure, B) . All long-term survivors but one were younger than 60 years; the 5-year and 10-year OS was 40% 6 10% for the 23 patients #60 years old and 15% 6 12% and 0% for the 18 patients .60 years old (p 5 0.0001).
According to the use of consolidation WBRT, 5 of the 7 patients who were not irradiated experienced relapse (local in 3, systemic in 2), 5 of them died of lymphoma (n 5 4) or myocardial infarction; 16 of 24 irradiated patients experienced relapse (local in 15, systemic in 1), 17 of them died of lymphoma (n 5 15), radionecrosis, or stroke. The 10-year PFS was 0% 6 11% for not irradiated patients and 28% 6 8% for irradiated patients, with a 10-year OS of 21% 6 11% and 29% 6 8%, respectively.
Survivors had no chronic hematologic or nonhematologic toxicities. At the last control (at 10 years of followup), hemograms and biochemical profiles did not show organ abnormalities, and MMSE showed values $29 in all patients but one; this patient had severe neuropsychological impairment after unrelated herpetic encephalitis. One patient had bitemporal hemianopia. All survivors but 2 worked again, with the same pre-PCNSL responsibility level in 5 cases.
DISCUSSION This phase II trial shows that MATILDE regimen followed by WBRT is a feasible and active strategy for patients #70 years old with PCNSL. These results, updated after a median follow-up of 12 years, confirm the originally reported survival plateau, 6 which could represent cure in PCNSL. All long-term survivors but one were followed by .10 years, and, with a single exception, showed excellent neurologic performance, when assessed by MMSE and capability to work again at the same responsibility level; the good quality of cognitive functions is strongly related to the fact that all long-term survivors but one were younger than 60 years at trial registration. Other forms of chronic toxicity were not detected.
Only a few reports updating results of PCNSL treatment after a median follow-up longer than 10 years are available. Sometimes, these updates have been associated with the disappearance of an originally reported survival plateau, which has been due to late relapses and unrelated deaths, both in trials addressing new chemo-radiotherapy combinations 2 and consolidation with HDC/ASCT. 3, 8 In these studies, the originally described plateaus have disappeared from all OS curves of analyzed subgroups (i.e., age, prognostic scores). 2, 3, 8 Updated results of the NABTT 96-07 trial have confirmed that late relapses also occur in patients with PCNSL treated with high-dose MTX alone, with only 20% of treated patients remaining relapse-free at a median follow-up of 6.8 years. 9 In the present trial, all recorded events but 4 occurred within the first 5 years of follow-up. The 4 late events were 2 deaths due to brain relapse at 67 and 110 months, an unrelated death while disease-free at 63 months, and a systemic (extraneural) relapse at 100 months that was successfully managed with high-dose polychemotherapy. Followup is longer than 10 years in 8 of the 9 survivors, which could be synonymous of cure in PCNSL. In effect, although late relapses affected 21% of patients followed by more than 5 years in a prospective trial, 3, 8 relapses after 10 years have been exceptional events in PCNSL, affecting 2 (0.7%) of 278 patients who had achieved CR after first-line treatment in an unselected retrospective series. 5 Owing to the rarity of this event and the unchanged survival plateau after an extended follow-up, we are confident that long-term survivors after MATILDE-WBRT can be considered cured of PCNSL. This experience confirms that reporting of long-term follow-up outcome is crucial to fully evaluate the potential for definitive cure of PCNSL by a new chemotherapy regimen.
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